Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Refractory/Relapse Neuroblastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 24fludarabine phosphate 22Filgrastim 15Gemcitabine 14fludarabine 13Rituximab 13Brentuximab Vedotin 13Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Bortezomib 10Mycophenolic Acid 9Melphalan 9Etoposide 9Busulfan 9Sirolimus 8Lenalidomide 8Azacitidine 8Nivolumab 7Dexamethasone 7pembrolizumab 6Radiotherapy 6Cytarabine 6Antilymphocyte Serum 6romidepsin 5aldesleukin 5Panobinostat 5Leucovorin 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hodgkin Disease × Biological Products × Clear all
NCT03383965 2017-12-27

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Immune Cell, Inc.

Phase 1 Unknown
20 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡